Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

NCT00983047 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped The sponsor decide to terminate

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Nimotuzumab and Docetaxel

Sponsor

Biotech Pharmaceutical Co., Ltd.